Shinnihonseiyaku Co., Ltd.

Shinnihonseiyaku Co., Ltd.

TTSE:4931
2,020.00
JPY
+1.00
(+0.05%)
130.38EPS
12.91P/E
36.42BMarket Cap
Nov 11Next Earn
Shinnihonseiyaku Co., Ltd.
TSE:4931
(Tokyo Stock Exchange)

Recent

price

2,020.00

P/E

ratio

12.91

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
1,358.44
3,107.59
2,097.25
1,565.61
1,571.33
1,683.73
1,751.28
1,857.68
1,940.44
1,814.18
Revenue per Share
70.73
174.39
113.98
98.49
107.69
109.91
111.35
129.67
120.46
130.8
Basic EPS, GAAP
102.44
82.86
96.73
119.37
88.13
89.02
151.72
77.24
211.97
- -
Free Cash Flow per Basic Share
67.05
30.48
22.06
17.5
29.76
32.41
32.93
32.89
45.8
- -
Dividend per Share
128.49
200.61
590.25
665.93
755.85
834.7
913.86
1,010.04
1,078.56
944.5
Book Value per Share
91.42
164.17
560.03
643.99
686.79
765.19
852.59
947.93
1,054.63
884.07
Tangible Book Value per Share
21
10
16
22
22
21
22
22
21
22
Basic Weighted Avg Shares
28,366
31,203
33,562
33,733
33,896
36,107
37,653
40,043
41,140
39,059
Sales/Revenue/Turnover
7.76
7.99
8.54
9.87
10.1
9.76
9.97
10.43
11.62
11.17
Operating Margin (%)
289
359
482
465
424
428
433
390
365
- -
Depreciation Expense
1,477
1,751
1,824
2,122
2,323
2,357
2,394
2,795
2,554
2,816
Net Income, GAAP
34.59
29.71
35.36
33.24
31.69
32.15
32.15
31.97
37.98
32.15
Effective Tax Rate (%)
5.21
5.61
5.43
6.29
6.85
6.53
6.36
6.98
6.21
7.21
Profit Margin (%)
855
2,190
10,149
11,737
13,816
15,290
16,171
18,189
19,160
16,943
Working Capital
1,284
1,109
936
762
1,839
1,443
254
76
2
165
LT Debt
2,683
4,189
12,756
14,265
16,178
17,917
19,659
21,791
22,807
20,366
Total Equity
- -
33.17
18.06
14.55
13.37
12.13
12.39
12.99
12.7
14.56
Return on Invested Capital (%)
- -
36.46
18.88
14.61
13.83
12.37
12.02
13.27
11.37
14.27
Return on Capital (%)
- -
50.96
21.53
15.71
15.26
13.83
12.74
13.49
11.45
14.6
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'23
Dec'24
Mar'24
ST Debt
192
184
182
LT Borrowings
254
212
165
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
32,870
37,086
36,419

Working Capital

JPY

•

in mil. unless spec.
Sep'23
Dec'24
Mar'24
Total Current Assets
21,254
20,726
21,574
Cash, Cash Equivalents & STI
15,518
14,537
15,648
Accounts Receivable, Net
3,171
3,300
3,317
Inventories
2,092
2,223
2,203
Total Current Liabilities
5,083
4,362
4,631
Payables & Accruals
- -
- -
- -
ST Debt
192
184
182
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.88%
4.66%
Free Cash Flow
- -
33.23%
169.91%
Net Income, GAAP
- -
4.13%
-8.62%
Sales/Revenue/Turnover
- -
4.07%
2.74%
Total Cash Common Dividend
- -
23.5%
36.95%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,941
9,715
- -
- -
40,043
2025
- -
- -
- -
- -
41,140
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36.36
28.71
- -
- -
129.67
2025
- -
- -
- -
- -
120.46
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
32.89
2025
- -
- -
- -
- -
45.8
2026
- -
- -
- -
- -
- -
Business
Shinnihonseiyaku Co., Ltd. Shinnihonseiyaku Co., Ltd. engages in the research, development, manufacturing, and sales of cosmetics, pharmaceuticals, and health foods primarily through mail order, wholesale, direct store sales, and overseas channels in Japan, China, Taiwan, and other Asian markets. Founded on March 11, 1992, and headquartered at 1-4-7 Otemon, Chuo-ku, Fukuoka, Japan, the company offers skincare products under the Perfect One and Perfect One Focus brands, including Platinum Collagen EX, Whitening Gel with 55 moisturizing ingredients, Super Moisture Gel with 60 moisturizing ingredients, and Lifting Gel; health foods such as supplements and green juice; and pharmaceutical products like Yokuininekisu Tablets SH for skin health, alongside remedies for dry skin, feelings of cold, joint and back pain, and menopause symptoms using Japanese and Chinese herbal materials. It operates with a customer database of approximately 6 million cases, conducts over 200,000 monthly call center conversations for personalized proposals, and emphasizes collagen research in partnership with Tokyo University of Agriculture and Technology, including the development of Compounding Collagen EX featuring seven collagen types for mature skin care. Recent developments include the introduction of a transfer-restricted stock compensation system for executives and employees in August 2025, an absorption-type merger of a wholly owned subsidiary with waiver of claims in August 2025, completion of a 487,000-share repurchase for 945.3 million yen in November 2024, authorization of a buyback plan for up to 540,000 shares representing 2.5% of capital in November 2024, and a special dividend announcement for the fiscal year ended September 30, 2024. The company maintains Type 2 Pharmaceuticals Manufacturing and Sales licenses, Quasi-drug Products Manufacturing and Sales licenses, and memberships in organizations such as the Japan Direct Marketing Association, Japan Health and Nutrition Food Association, and Japan Cosmetic Industry Association, with 507 employees as of September 2024.